Source Code Name Case count Share of cases (%)
REIMB REIMB_KELA(202)_ICD10(M45) Connective tissue diseases, rheumatoid arthritis and comparable disease, Ankylosing spondylitis 857
REIMB REIMB_KELA(313)_ICD10(M45) Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Ankylosing spondylitis 621
REIMB REIMB_KELA(281)_ICD10(M45) Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Ankylosing spondylitis 596
REIMB REIMB_KELA(313)_ICD10(M450) Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Name not found 16
REIMB REIMB_KELA(281)_ICD10(M450) Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Name not found 14
REIMB REIMB_KELA(202)_ICD10(M450) Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found 7